- Company
- Reorganization of multinational companies & plans
- by Nov 19, 2020 06:10am
- A meeting is held to discuss ways to improve workers' environment related to reorganization of multinational pharmaceutical companies. Yoon Joonbyeong, a member of the National Assembly's Environment and Labor Committee, announced that the meeting will be held on the 18th at 10:00 am in the 2nd conference room of the Seoul Metropolitan Counci
- Company
- Sanofi to stand alone Consumer Healthcare and offer ERP
- by Nov 18, 2020 12:19pm
- Sanofi is reportedly planning to spin off the Consumer Healthcare (CHC) businesses and offer early retirement program (ERP) to employees under CHC and General Medicine (GenMed). On Nov. 13, Sanofi-Aventis Korea notified all employees the global Sanofi CHC stand alone plan that would also affect the South Korean branch as well. Sanofi
- Company
- All bets are off for patent dispute of Galvus
- by Kim, Jin-Gu Nov 18, 2020 06:36am
- The patent dispute over the DPP-4 inhibitor-based diabetes treatment'Galvus (Vildagliptin)' turns around and ends at the KIPO. The Patent Court of Korea sided with Novartis, and Ahn-gook, who lost, gave up the Supreme Court appeal, and the KIPO finally took over the case again. According to the pharmaceutical industry on the 17th, Ahn-
- Company
- General hospitals pass antifungal Cresemba for prescription
- by Eo, Yun-Ho Nov 18, 2020 06:35am
- South Korean general hospitals have started registering Pfizer’s novel antifungal Cresemba for prescription. According to pharmaceutical industry sources, the Drug Committee (DC) at the Big Five general hospitals and other healthcare institutes in South Korea, including Seoul Asan Medical Center and Severance Hospital, have cleared Cres
- Company
- How can the domestic drug price system be improved?
- by Nov 17, 2020 06:28am
- As drugs that target specific genes or activate the immune system to treat diseases have been released, the use of one drug for various types of cancer has become more frequent. As of 2018, 75% of target anticancer drugs are multiple indications, and in the case of immune anticancer drugs, thousands of single and combined clinical trials for var
- Company
- A heated panel discussion on indication-basis drug pricing
- by Eo, Yun-Ho Nov 17, 2020 06:27am
- In this day and age of a single drug offering a variety of indications, the problem now lies on the drug pricing. The negotiation between the South Korean government and pharmaceutical company is slowing down and the patients have to wait longer as the country’s drug pricing system cuts the pricing when a drug expands its uses. On Nov.
- Company
- Korus Pharm is in charge of Russian COVID-19 vaccine
- by Kim, Jin-Gu Nov 17, 2020 06:27am
- It was confirmed that Korus Pharm, a small and medium-sized pharmaceutical company, is in charge of the Korean production of the Corona 19 vaccine developed by Russia. According to the pharmaceutical industry on the 13th, GL Rapha signed a three-party contract with the Russian Direct Investment Fund (RFID) and Yas Pharmaceuticals of the U
- Company
- Amgen-CKD ink co-promotion deal on Evenity
- by Nov 16, 2020 06:03am
- On Nov. 12, Amgen Korea (General Manager Noh Sang-kyung) and Chong Kun Dang (CEO Kim Young-joo) announced they signed a co-promotion agreement on a novel osteoporosis drug Evenity (romososumab) on Nov. 11. The two companies also renewed the Prolia (denosumab) co-promotion deal as well. According to the agreement, Amgen Korea would fo
- Company
- Dong-A ST introduces SHR-1701 in China
- by Chon, Seung-Hyun Nov 16, 2020 06:02am
- Dong-A ST announced on the 11th that it has signed a contract with Jiangsu Hengrui Medicine to introduce the next-generation immune anticancer drug 'SHR-1701' in Korea. With this contract, Dong-A ST has secured the exclusive domestic development and sales rights of fusion protein, which is undergoing phase I and II clinical trials in China by
- Company
- GA leads newly appointed at KRPIA and global companies
- by Eo, Yun-Ho Nov 11, 2020 06:10am
- Multinational pharmaceutical companies in South Korea are busy processing a wave of new recruit changes, specifically happening around government affairs jobs. The pharmaceutical industry sources reported many of pharmaceutical companies, as well as Korean Research-based Pharmaceutical Industry Association (KRPIA), have announced a seri
